Her 2 Positive Advanced Breast Cancer: From Evidence to Practice
|
|
- Meryl Carson
- 6 years ago
- Views:
Transcription
1 Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine, University of Calgary, Canada Department of Oncology University of Calgary
2 Disclosures Advisory Board: Amgen, Astra Zeneca, BI, BMS, Eisai, Merrimack, Novartis, Pfizer, Roche, Spectrum
3 Clinical Management of Her 2+ Metastatic Breast Cancer Giordano et al. JCO 2014 (ASCO GUIDELINES)
4 Outline First Line Treatment Second Line Treatment and Beyond Individualized Approach An Algorithm and Concluding Remarks
5 Outline First Line Treatment Second Line Treatment and Beyond Individualized Approach An Algorithm and Concluding Remarks
6 Trastuzumab prolongs overall survival in HER2-positive MBC 100 Chemotherapy (n = 234) Chemotherapy + trastuzumab (n = 235) Overall survival (%) Median OS: 20.3 months RR = 0.80 (95% CI = 0.64,1.00) p = Median OS: 25.1 months Time (months after enrolment) OS was a secondary endpoint in the study Chemotherapy = either doxorubicin or epirubicin + cyclophosphamide or paclitaxel OS, overall survival; RR, relative risk of death Adapted from Slamon DJ, et al. N Engl J Med 2001; 344:
7 Recent Trials in First Line Her 2 positive MBC First Line MA.31 Taxane + Trastuzumab vs. Taxane + Lapatinib NEFERT-T Taxane + Trastuzumab vs. Taxane + Neratinib BOLERO-1 Paclitaxel + Trastuzumab vs. Paclitaxel + Trastuzumab + Everolimus CLEOPATRA Docetaxel + Trastuzumab vs. Docetaxel + Trastuzumab + Pertuzumab MARIANNE Docetaxel/Paclitaxel + Trastuzumab vs. T-DM1 vs. T-DM1 + Pertuzumab PERUSE Taxane + Trastuzumab + Pertuzumab 7
8 1 st line Pertuzumab + Trastuzumab (CLEOPATRA) HER2+ (central) LABC or MBC (N=808) 1:1 n=402 Pertuzumab+trastuzumab (840 mg 420 mg q3wks) Docetaxel 6 cycles PD 1 year from completion of adjuvant trastuzumab n=406 Placebo+trastuzumab (8 mg/kg 6 mg/kg q3wks) Docetaxel 6 cycles PD Important points: ~ 90% of patients did not receive trastuzumab in (neo) adjuvant setting ~ 50% of patients did not receive any prior (neo) adjuvant chemotherapy Patients with CNS metastases were excluded Baselga et al. N Engl J Med 2012;366:109. 8
9 1st-line Pertuzumab + Trastuzumab (CLEOPATRA) Progression-free survival 1 Overall survival 2 Progression-free survival (%) Pertuzumab+trastuzumab+ docetaxel Placebo+trastuzumab+docetaxel Time (months) OS (%) Pertuzumab+trastuzumab+ docetaxel Placebo+trastuzumab+docetaxel Time (months) Pertuzumab+ trastuzumab+docetaxel Placebo+ trastuzumab+docetaxel Hazard ratio P-value ORR % 69.3% PFS months 12.4 months 0.69 < OS months 40.8 months Most common adverse events Grade 3 in the pertuzumab+trastuzumab+docetaxel group: 1 Neutropenia (48.9%), febrile neutropenia (13.8%), leukopenia (12.3%) and diarrhoea (7.9%) Median follow-up: 30 months. PFS, progression-free survival; OS, overall survival. 1. Baselga et al. N Engl J Med 2012;366:109; 2. Swain et al. NEJM 2015;724:734. 9
10 Cleopatra Overall Survival Cross over patients (11%) excluded Swain et. al NEJM 2015
11 MARIANNE: Phase III study of T-DM1 with or without Pertuzumab vs Taxane and Trastuzumab (no Pertuzumab) HER2-positive progressive or recurrent locally advanced BC or previously untreated MBC (n=1092) R Trastuzumab + taxane (n=364) T-DM1 + pertuzumab (n=364) T-DM1 + placebo (n=364) Trastuzumab + Taxane T-DM1 + Placebo Ellis et al ASCO 2015, Breast Cancer Oral Session Monday June 1, 2015 T-DM1 + Pertuzumab Hazard ratio ORR 67.9% 59.7% 64.2% NR NR PFS 13.7 m 14.1m 15.2m HR 0.91 HR 0.87 OS HR 0.93 HR P-value p=0.31 p=0.14 P NS p NS 11
12 MARIANNE Trial Progression Free Survival Perez E et al, JCO 2016
13 Final Analysis of Overall Survival Presented By Edith Perez at 2017 ASCO Annual Meeting
14 Anti-Cancer Therapy During Follow-Up Presented By Edith Perez at 2017 ASCO Annual Meeting
15 PERUSE: 1L pertuzumab and trastuzumab with taxane therapy in HER2-positive labc or mbc PERUSE tests the safety and efficacy of pertuzumab and trastuzumab when combined with investigator s choice of taxane in 1L HER2-positive mbc The study is a post-approval measure for the EMA to support the label in Europe It expands on the information obtained from CLEOPATRA by providing safety and efficacy data for combination of PH with taxanes other than docetaxel Phase IIIb study design: Male or female patients with HER2-positive mbc (N = 1436) Primary endpoint: Safety, tolerability Secondary objectives: PFS, OS, BOR Pertuzumab + trastuzumab + taxane* (docetaxel or paclitaxel or nab-paclitaxel) * Investigator s choice of taxane * Investigator s choice of taxane T Bachelot, et al. Poster presentation, Abstract P SABCS 2016
16 PERUSE preliminary data: Efficacy Median follow-up: 17.2 months Progression-free survival ITT population by taxane Total Censored Event s Median (95% CI) Docetaxel (43.0%) (17.45, 22.87) Paclitaxel (44.3%) (20.67, 26.25) Nabpaclitaxel (38.5%) (12.22, 34.23) n at risk Months Docetaxel Paclitaxel Nab-paclitaxel Median PFS = 21.2 months in all patients who received at least one dose of study treatment
17 Summary First Line The standard of care should consist of pertuzumab and trastuzumab along with a taxane T-DM1 looks very promising in the first line and may be suited for selected patients Not candidates for chemotherapy DFI < 6 months Contraindication to taxanes? Previous (neo) adjuvant Pertuzumab 17
18 Future Questions First Line Duration of targeted therapy for those responding Duration of chemotherapy when receiving dual targeted therapy Combination of endocrine therapy with dual targeted anti-her 2 tx for ER+/Her 2 +ve pts (PERTAIN) 18
19 Outline First Line Treatment Second Line Treatment and Beyond Individualized Approach An Algorithm and Concluding Remarks
20 Prior exposure to trastuzumab (adj +/- metastatic) Comparison of patient populations EMILIA (NEJM 2012) BOLERO 3 (ASCO 2014) LUX Breast (SABCS 2014) TH3RESA (Lancet Oncol 2014) EGF (JCO 2012) Control Capecitabine + Lapatinib Vinorelbine + Trastuzumab Vinorelbine + Trastuzumab Physician s choice Lapatinib alone Experimental T-DM1 Vinorelbine + Trastuzumab + Everolimus Vinorelbine + Afatinib T-DM1 Lapatinib + Trastuzumab Prior anti-her2 with relapse < 1 year Prior anti-her2 with relapse on therapy Yes Yes Yes Yes Yes Yes Previous TRAS and Taxane Adapted from M. Piccart St. Gallen 2015 Presentation Yes Mean of 1.6 lines of previous trastuzumab regimens Yes 1 previous TRAS regimen Yes Median of 4 regimens for advanced breast cancer Yes Median of 3 previous trastuzumab regimens for metastatic
21 T-DM1 vs. Capecitabine and Lapatinib (EMILIA) HER2-positive (central) LABC or MBC (N=980) n=495 T-DM1 3.6 mg/kg q3w IV PD Prior taxane and trastuzumab Progression on metastatic therapy or within 6 months of adjuvant therapy 1:1 n=496 Lapatinib 1250 mg/day orally qd Capecitabine 1000 mg/m 2 orally bid, days 1 14, q3w PD Primary endpoint: independently assessed PFS, OS, safety Key secondary endpoints: investigator-assessed PFS, ORR LABC, locally advanced breast cancer; MBC, metastatic breast cancer; T-DM1, trastuzumab emtansine; IV, intravenous; PD, progressive disease; qd, once daily; bid, twice daily; PFS, progression-free survival; OS, overall survival; ORR, objective response rate. Verma et al. N Engl J Med 2012;367:
22 EMILIA Results Progression-free survival Overall survival Proportion progression-free T-DM1 Lapatinib+capecitabine Time (months) Proportion surviving % 78.4% 64.7% 51.8% T-DM1 Lapatinib+capecitabine Time (months) T-DM1 Lapatinib+capecitabine Hazard ratio P-value PFS 9.6 months 6.4 months 0.65 <0.001 OS 30.9 months 25.1 months 0.68 <0.001 Most common adverse events Grade 3: T-DM1: thrombocytopenia (12.9%) and transaminitis (4.3%) Lapatinib+capecitabine: diarrhoea (20.7%) and hand foot syndrome (16.4%) PFS, progression-free survival; OS, overall survival; T-DM1, trastuzumab emtansine. Verma et al. N Engl J Med 2012;367:
23 T-DM1 vs. Physician Tx of Choice (TH3ERESA) HER2-positive (central) advanced breast cancer (N=602) n=404 T-DM1 3.6 mg/kg q3w IV PD 2 prior HER2-directed therapies for advanced BC 2:1 Prior treatment with trastuzumab, lapatinib, taxane n=198 Physician s choice PD T-DM1 (optional crossover) Primary endpoint: investigator evaluated PFS and OS Key secondary endpoints: ORR and safety *Physician s choice could have been single-agent chemotherapy, hormonal therapy, or HER2-directed therapy, or a combination of a HER2- directed therapy with a chemotherapy, hormonal therapy, or other HER2-directed therapy. BC, breast cancer; T-DM1, trastuzumab emtansine; IV, intravenous; PD, progressive disease; PFS, progression-free survival; OS, overall survival; ORR, overall response rate. Krop IE et al. Lancet Oncol 2014; 15:
24 TH3RESA interim results PFS by investigator assessment First interim OS analysis Proportion progression-free T-DM1 Physicians choice Time (months) Proportion surviving Observed 21% of targeted events T-DM1 Physicians choice Time (months) T-DM1 Physicians choice * Hazard ratio P-value PFS 6.2 months 3.3 months 0.53 < OS (immature) NE 14.9 months (NS) T-DM1, trastuzumab emtansine; PFS, progression-free survival; OS, overall survival; NE, not evaluable. *68.5% chemo + T. 10.3% T + L. 2.7% chemo + L Krop IE et al. Lancet Oncol 2014; 15:
25 TH3RESA SABCS 2015 Update Weilders et al SABCS
26 PHEREXA: A clinical trial of pertuzumab in second-line metastatic breast cancer Arm A: Pertuzumab + trastuzumab + capecitabine HER2-positive MBC (N = 450) R Arm B: Trastuzumab + capecitabine Last patient in Q3
27 PHREXA Summary Primary Endpoint Progression Free Survival (Independent Review) Progression Free Survival (Investigator) Overall Survival Capecitabine+Trast uzumab Capecitabine+Tras tuzumab+pertuzu mab HR p-value 9.0 m 11.1 m 0.82 ( ) p= P= m 36.1 m 0.68 NE Toxicity: Increased rates of Grade 3 and greater toxicity with Cape+Tras+Pert: Diarrhea, LVSD
28 Pertuzumab for Advanced Breast Cancer PHREXA and CLEOPATRA Capecitabine +Trastuzuma b Capecitabine+ Trastuzumab+ Pertuzumab HR p-value Docetaxel + Trastuzuma b +Placebo Docetaxel + Trastuzumab +Pertuzumab HR p-value Primar y Endpoi nt PFS (Indepe ndrevi ew) 9.0 m 11.1 m 0.82 ( ) p= m 18.7 m 0.69 p< Overall Surviv al 28.1 m 36.1 m 0.68 NE 40.8 m 56.5 m 0.66 p= Presented by Sunil Verma, MD Swain et. al NEJM 2015
29 T-DM1 Post Pertuzumab Data from CLEOPATRA and PHREXA Studies
30 T-DM1 Post Pertuzumab Data from CLEOPATRA and PHREXA Studies
31 T-DM1 Post Pertuzumab Data from CLEOPATRA and PHREXA Studies
32 Response Rate Median Duration of Treatment : 4.0 months 35% of patients had treatment beyond six months post Pertuzumab
33 Her 2 Positive Metastatic Breast Cancer Significant gains in Survival
34 Outline First Line Treatment Second Line Treatment and Beyond Individualized Approach An Algorithm and Concluding Remarks
35 Individualized Approach Prior adjuvant therapy Hormone Receptor Status
36 Her 2 Positive Metastatic Breast Cancer Key Clinical Scenarios Presents with de novo metastasis No previous TRAS Develops metastasis following adjuvant therapy Adjuvant without TRAS TRAS-free Interval 1yr Adjuvant TRAS < 1yr Different sensitivities to anti-her2 drugs? Adapted from M. Piccart St. Gallen 2015 Presentation 36
37 Comparison of patient populations Limited prior Adjuvant Trastuzumab Therapy MARIANNE (ASCO 2015) CLEOPATRA (NEJM 2015) BOLERO-1 (SABCS 2014) MA-31 (ASCO 2012) Chemo Docetaxel/Pacl itaxel Docetaxel Paclitaxel Taxane Anti-HER2 regimens tested T-DM1 or T-DM1 + Pertuzumab Trastuzumab + Pertuzumab (vs TRAS) Trastuzumab + Everolimus 10mg OD (vs TRAS) Lapatinib (vs TRAS) De novo metastatic Prior adj. trast. (and interval >1y) 55% 53% 50% 43% 31% 11% 10% 18% The results of most of these trials are relevant today only for de novo metastatic patients Adapted from M. Piccart St. Gallen 2015 Presentation
38 Prior Trastuzumab Efficacy Data Adjuvant Trastuzumab DFI > 1year MARIANNE (ASCO 2015) CLEOPATRA (NEJM 2015) 1 BOLERO1 (SABCS 2014) MA-31 (ASCO 2012) PFS 10.3 months vs 15.2 months (T-DM1) 10.4 months vs months (p value not reported) NR NR OS 40.8 months vs 52.3 months (p=ns) 46.6 months vs months (p value not reported) NR NR 1 Swain et al NEJM Correspondence 2015
39 T-DM1 and PFS: effect of prior therapies Presented By Paul Ellis at 2015 ASCO Annual Meeting
40 OS Subgroup Analyses by Baseline Risk Factors <br />T-DM1 vs HTa Presented By Carlos Barrios at 2017 ASCO Annual Meeting
41 Response to T-DM1 lasts longer Presented By Paul Ellis at 2015 ASCO Annual Meeting
42 EMILIA: Progression-Free Survival Subgroup Analyses Cap + Lap T-DM1 Baseline characteristic All pts Total n 991 Median, mos 6.4 Median, mos HR (95% CI) (0.56, 0.78) Prior Trastuzumab T-DM1 better Cap + Lap better Age <65 yrs 65 yrs (0.52, 0.74) 1.06 (0.68, 1.66) ER and PR status ER+ and/or PR+ ER and PR (0.58, 0.91) 0.56 (0.44, 0.72) Line of therapy a First Second Third (0.30, 0.85) 0.69 (0.53, 0.91) 0.69 (0.55, 0.86) Data cut-off Jan 14, 2012 HRs were from unstratified analysis. a Defined as any systemic therapy, including endocrine or chemotherapy. Hazard ratio Verma et al. N Eng J Med 2012 (incl. supplementary appendix) Blackwell et al. ASCO 2012; Abst #LBA1
43 Prior Trastuzumab EMILIA: Overall Cap + Lap Survival T-DM1 Subgroup Analyses Baseline Total Median Median HR T-DM1 Cap + Lap characteristic n (mos) (mos) (95% CI) Better Better All patients (0.56, 0.87) Age group <65 years (0.52, 0.83) years NR 0.74 (0.37, 1.47) 75 years 25 NR (0.94, 12.65) ER and PR status ER+ and/or PR (0.46, 0.85) ER and PR (0.54, 1.03) Line of therapy a First-line NR 0.61 (0.32, 1.16) Second-line 361 NR (0.61, 1.27) Third- and later-line (0.46, 0.84) Hazard ratio a Defined as any systemic therapy including endocrine and chemotherapy. NR, not reached. From confirmatory OS analysis; data cut-off July 31, Verma et al. ESMO 2012; Oral Abstract #LBA12
44 CLEOPATRA PFS in predefined subgroups Prior (neo)adjuvant chemotherapy Region Age group Race All No Yes Europe North America South America Asia <65 years 65 years <75 years 75 years White Black Asian Other Favors pertuzumab Favors placebo Hormone Receptor Status n HR 95% CI Disease type ER/PgR status HER2 status Visceral disease Non-visceral disease Positive Negative IHC 3+ FISH-positive ER, estrogen receptor; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; PFS, progression-free survival; PgR, progesterone receptor 44 Swain et al. SABCS 2012 Poster P
45 CLEOPATRA Overall survival in predefined subgroups Favors pertuzumab Favors placebo Hormone Receptor Status n HR 95% CI Prior (neo)adjuvant chemotherapy Region Age group Race All No Yes Europe North America South America Asia <65 years 65 years <75 years 75 years White Black Asian Other Disease type ER/PgR status HER2 status Visceral disease Non-visceral disease Positive Negative IHC 3+ FISH-positive ER, estrogen receptor; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; PgR, progesterone receptor 45 Swain et al. SABCS 2012 Poster P
46 EMILIA Progression-Free Survival Subgroup Analyses Baseline characteristic All pts Total n 991 Cap + Lap Median, mos 6.4 T-DM1 Median, mos HR (95% CI) (0.56, 0.78) Hormone Receptor Status T-DM1 better Cap + Lap better Age <65 yrs 65 yrs (0.52, 0.74) 1.06 (0.68, 1.66) ER and PR status ER+ and/or PR+ ER and PR (0.58, 0.91) 0.56 (0.44, 0.72) Line of therapy a First Second Third (0.30, 0.85) 0.69 (0.53, 0.91) 0.69 (0.55, 0.86) Data cut-off Jan 14, 2012 HRs were from unstratified analysis. a Defined as any systemic therapy, including endocrine or chemotherapy. Hazard ratio Verma et al. N Eng J Med 2012 (incl. supplementary appendix) Blackwell et al. ASCO 2012; Abst #LBA1
47 EMILIA Overall Survival Subgroup Analyses Cap + Lap T-DM1 Baseline Total Median Median HR characteristic n (mos) (mos) (95% CI) All patients (0.56, 0.87) Age group <65 years (0.52, 0.83) years NR 0.74 (0.37, 1.47) 75 years 25 NR (0.94, 12.65) ER and PR status ER+ and/or PR (0.46, 0.85) ER and PR (0.54, 1.03) Line of therapy a First-line NR 0.61 (0.32, 1.16) Second-line 361 NR (0.61, 1.27) Third- and later-line (0.46, 0.84) Hormone Receptor Status T-DM1 Better Cap + Lap Better Hazard ratio From confirmatory OS analysis; data cut-off July 31, 2012.
48 HER2 ER Cross-talk Presented By Karen Gelmon at 2017 ASCO Annual Meeting
49 Single Agent HER2 targeted therapy adds modestly to endocrine therapy Presented By Karen Gelmon at 2017 ASCO Annual Meeting
50 ALTERNATIVE: Study Design Gradishar Abstract 1004 Presented By Karen Gelmon at 2017 ASCO Annual Meeting
51 ALTERNATIVE: Baseline Characteristics Presented By Karen Gelmon at 2017 ASCO Annual Meeting
52 ALTERNATIVE: Secondary Endpoint<br />PFS in all treatment arms Presented By Karen Gelmon at 2017 ASCO Annual Meeting
53 ALTERNATIVE: Secondary Endpoint<br />OS in all treatment arms Presented By Karen Gelmon at 2017 ASCO Annual Meeting
54 PERTAIN Study Design (Phase II) Presented By Karen Gelmon at 2017 ASCO Annual Meeting
55 Primary PFS Analysis (Stratified, ITT Population) Presented By Karen Gelmon at 2017 ASCO Annual Meeting
56 Summary HT and HER2 directed therapy Presented By Karen Gelmon at 2017 ASCO Annual Meeting
57 Outline First Line Treatment Second Line Treatment and Beyond Individualized Approach An Algorithm and Concluding Remarks
58 ASCO Clinical Practice Guidelines First Line Clinicians should recommend the combination of Trastuzumab, Pertuzumab and a Taxane for first line treatment, unless the patient has a oontraindication to Taxanes Type: Evidence quality: Strength of Recommendation: Evidence Based High Strong If a patient finished trastuzumab-based adjuvant treatment < 12 months before recurrence, clinicians should follow the second line Her 2 targeted therapy based treatment recommendations. Type: Evidence quality: Strength of Recommendation: Evidence Based Intermediate Moderate Giordano et al. J Clin Oncol 2014;32:2078
59 ASCO Clinical Practice Guidelines Second Line and Beyond If a patient s Her 2 positive advanced breast cancer has progressed during or after first-line Her 2 targeted therapy, clinicians should recommend trastuzumab emtansine (T-DM1) as second line treatment. Type: Evidence quality: Strength of Recommendation: Evidence Based High Strong If a patient s Her 2 positive advanced breast cancer has progressed during or after second line or greater Her 2 targeted therapy, but she has not received T-DM1, clinicians should offer T-DM1. Type: Evidence quality: Strength of Recommendation: Evidence Based High Strong Giordano et al. J Clin Oncol 2014;32:2078
60 ASCO Clinical Practice Guidelines Second Line and Beyond If a patient s Her 2 positive advanced breast cancer has progressed during or after second line or greater Her 2 targeted therapy, but she has not received Pertuzumab, clinicians may offer pertuzumab. Type: Evidence quality: Strength of Recommendation: Informal Consensus Insufficient Weak If a patient s Her 2 positive advanced breast cancer has progressed during or after second line or greater Her 2 targeted therapy, but she has already received pertuzumab and T-DM1, clinicians should recommend third-line or greater Her 2 targeted therapy-based treatment There is insufficient evidence to recommend one regimen over another Type: Evidence quality: Strength of Recommendation: Informal Consensus Insufficient Weak Giordano et al. J Clin Oncol 2014;32:2078
61 Real World Evidence European Data on outcomes of MBC patients ASCO 2017
62 Real World Evidence European Data on outcomes of MBC patients Delaloge et al, ASCO 2017
63 SEER Database: Her 2 Positive MBC Outcomes ASCO 2017
64 HER2 Positive De NOVO Stage IV disease <br />3-yr OS by stage and subtype Presented By Karen Gelmon at 2017 ASCO Annual Meeting
65 Clinical Pathway HER2+ MBC: 2015
66 Her 2 MBC 2017 Update DFI < 12 months T-DM1 (1 st line?)? Role of Pz post Role of Triplet Tx -Tras+Lap+AI - Tras + Pert + AI
67 Conclusion There is clear evidence that integration of Her 2 targeted therapy leads to significant clinical benefit Improved benefit with time with now real world evidence that confirms benefit We need to continue to investigate specific biomarkers to enhance the value of these therapies Our ability to sequence therapy should be based on improved understanding of treatment resistance and tumor biology along with patient consideration
68 Visit us in Calgary!
Targe:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationAdvances in the Management of Metastatic Her 2 Positive Breast Cancer
Advances in the Management of Metastatic Her 2 Positive Breast Cancer Sunil Verma MD, MSEd, FRCPC Medical Oncologist Research Lead, Division of Medical Oncology Chair, Breast Medical Oncology Sunnybrook
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationPROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
More informationUpdate in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationAdvanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationNew Drug Development in HER2+ Breast Cancer
New Drug Development in HER2+ Breast Cancer Philippe Aftimos, M.D. Senior Research Physician Clinical Pharmacology Unit Institut Jules Bordet Background Amplification of HER2 occurs in approximately 20%
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationHer 2 Positive Metastatic Breast Cancer
Her 2 Positive Metastatic Breast Cancer Alison Jones November 2013 Mrs Hermione Positive (then and now!) Diagnosed 2007 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2010metastatic
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More informationEmerging Agents in HER2-positive Disease. Mary Cianfrocca, DO Director, Breast Oncology Program Banner MD Anderson Cancer Center Gilbert, AZ
Emerging Agents in HER2-positive Disease Mary Cianfrocca, DO Director, Breast Oncology Program Banner MD Anderson Cancer Center Gilbert, AZ Signal Transduction by the HER Family and Potential Mechanisms
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Management of HER2+ MBC SOBO 2012 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for Women s Cancer
More informationEnfermedad con sobreexpresión de HER-2 neu
Enfermedad con sobreexpresión de HER-2 neu Elsa Dalmau Parc Taulí Sabadell. Hospital Universitari. Enfermedad con sobreexpresión de HER-2 neu ÍNDICE Neoadyuvancia Adyuvancia Enfermedad avanzada Enfermedad
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
More informationNuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento
Nuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento Prof. Sabino De Placido Dip. di Endocrinologia ed Oncologia
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationIl trattamento medico
III Sessione: La malattia in fase avanzata Il trattamento medico Emilio Bria Oncologia, Dipartimento di Medicina, Università di Verona, Azienda Ospedaliera Universitaria Integrata Verona emilio.bria@univr.it
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationDisease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
More informationJosé Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
More informationSYSTEMIC THERAPY FOR HER-2+ ABC
SYSTEMIC THERAPY FOR HER-2+ ABC F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & NR Committee Chair EORTC
More informationPresent and emerging treatment options in Her-2/neu overexpressing metastatic breast cancer
Present and emerging treatment options in Her-2/neu overexpressing metastatic breast cancer Christoph C. Zielinski Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center,
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More informationInnovations In The Management Of
Innovations In The Management Of HER2+ Breast Cancer Dr. Sandeep Goyle Consultant Medical Oncologist Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute Mumbai, India Introduction - Self
More informationSystemic therapy for HER2+ Advanced Breast Cancer
Systemic therapy for HER2+ Advanced Breast Cancer F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESMO Board of Directors & NR Committee Chair ESO Breast Cancer Program
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationCáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
More informationKarcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski
Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationPIK3CA Mutations in HER2-Positive Breast Cancer
2016.4.29. GBCC PIK3CA Mutations in HER2-Positive Breast Cancer Seock-Ah Im, MD, PhD. Department of Internal Medicine Seoul National University Hospital Contents Introduction TCGA data HER2 signaling pathway
More informationBreast cancer update. Iryna Kuchuk, MD Oncology department Meir Medical Center
Breast cancer update Iryna Kuchuk, MD Oncology department Meir Medical Center Overview Cancer Death Rates* Among Women, US,1930-2009 Factors Associated with Reduction In Breast Cancer Mortality Early
More informationEndocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationPage. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck
Hormone Therapy Resistance: Challenges and Opportunities Pamela. N. Munster, MD University of California, San Francisco Financial Disclosures Research Support From Merck Objectives: Understanding the current
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationDEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO CÁNCER DE MAMA HER 2 POSITIVO
DEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO CÁNCER DE MAMA HER 2 POSITIVO DEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO
More informationTITLE: Systemic Therapy for Patients with Advanced HER2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
TITLE: Systemic Therapy for Patients with Advanced HER2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Table of Contents Data Supplement 1: Additional Evidence
More informationPositive HER-2 tumor. How to incorporate the new drugs into neoadjuvance
Oncology Department Vall d Hebron University Hospital Barcelona. Spain Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance Javier Cortés June/2013 MD Anderson experience Buzdar et
More informationSessione 4: La malattia metastatica. La malattia HER2-positiva: strategia terapeutica nella pratica clinica e il futuro G.
Sessione 4: La malattia metastatica La malattia HER2-positiva: strategia terapeutica nella pratica clinica e il futuro G. RICCIARDI UOC Oncologia Medica, A.O. Papardo, Messina Dir. Prof. V. Adamo giusyricciardi81@hotmail.it
More informationTarget biologico e meccanismo d azione dei farmaci anti-her2: il continuum dal setting Neoadiuvante alla malattia metastatica
Target biologico e meccanismo d azione dei farmaci anti-her2: il continuum dal setting Neoadiuvante alla malattia metastatica Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental
More informationMetronomic chemotherapy for breast cancer
Metronomic chemotherapy for breast cancer M. Colleoni International Breast Cancer Study Group (IBCSG), Division of Medical Senology, European Institute of Oncology Metronomic Scheduling and Inhibition
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationHER2 Biology and Treatment in Breast Cancer
HER2 Biology and Treatment in Breast Cancer Sandra M. Swain, MD, FACP Director, Washington Cancer Institute Washington Hospital Center Professor of Medicine Georgetown University Washington DC Off-Label
More informationSustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA
Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine
More informationBreast Cancer: Chemotherapy and Novel Agents
North Carolina Oncology Association & South Carolina Oncology Society Joint Membership Meeting ~ February 26 27, 2010 The Ballantyne Resort ~ Charlotte, NC Breast Cancer: Chemotherapy and Novel Agents
More information2014 San Antonio Breast Cancer Symposium Review
2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
More informationMetastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2. - Valentina Sini -
Metastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2 - Valentina Sini - Metastatic Breast Cancer ER- Her2-20% ER- Her2+ ER+ Her2+ 5% 15% ER+ Her2- ER+ Her2+ ER- Her2+
More informationPost-ESMO 2012: Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich T.Rordorf, SAMO Luzern 1
Post-ESMO 2012: Breast Cancer Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich 1 Neoadjuvant treatment (in Her-2 positive disease) neoadjuvant trials abstracts: breast sparing surgery, biomarkers,
More informationThe Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationCancer du sein métastatique et amélioration de la survie Pr. X. Pivot
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999
More informationPolicy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015
Medication Policy Manual Topic: Perjeta, pertuzumab Committee Approval Date: May 9, 2014 Policy No: dru281 Date of Origin: September 24, 2012 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationTargeted Agents In Breast Cancer. Wonderful Music With New Instruments
Targeted Agents In Breast Cancer Wonderful Music With New Instruments 1 Trends In Cancer Mortality In Women in US At This Rate We Will Beat Breast Cancer In 2040 Is the cause screening?? Is the cause better
More informationRIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
More informationEndocrine treatment might NOT be the preferred option in Hrpos MBC. Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015
Endocrine treatment might NOT be the preferred option in Hrpos MBC Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015 Overall survival not improved by the AI treatment Benefit in
More informationJ Clin Oncol 32: by American Society of Clinical Oncology INTRODUCTION
VOLUME 32 NUMBER 19 JULY 1 2014 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I A L A R T I C L E Sharon H. Giordano and Ana M. Gonzalez-Angulo, University of Texas MD Anderson Cancer Center, Houston; Debra
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationMEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014
MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014 Dr Thomas Yau Clinical Assistant Professor MBBS(HK), MRCP (UK), FHKCP (Med Onc), FHKAM( Medicine), FRCP(London) Queen Mary Hospital The University of Hong Kong
More informationWhat is the Next Goal for HER2 Targeted Therapy?
What is the Next Goal for HER2 Targeted Therapy? Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education University of California San Francisco Helen Diller Family Comprehensive Cancer
More informationTreatment of Early-Stage HER2+ Breast Cancer
Treatment of Early-Stage HER2+ Breast Cancer Chau T. Dang, MD Chief, MSK Westchester Medical Oncology Service Breast Medicine Service Memorial Sloan Kettering Cancer Center Disclosures I have research
More informationNeoadjuvantTreatment In BC When, How, Who?
NeoadjuvantTreatment In BC When, How, Who? Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service, MSKCC Professor of Medicine, Weill Cornell Medical College President, ASCO 15 Potential Benefits Of
More informationLo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento
Lo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento TRASTUZUMAB most important breakthrough in the management of BC Trastuzumab
More informationChallenges and Success: Treatment of Metastatic Breast Cancer 2012
Challenges and Success: Treatment of Metastatic Breast Cancer 2012 Hope S. Rugo University of California San Francisco Helen Diller Family Comprehensive Cancer Center This presentation is the intellectual
More informationKazuhiro Araki, Yasuo Miyoshi
Editorial Abundant options to avoid toxicity and alternative strategies for human epidermal growth factor receptor 2-positive and hormone receptor-positive advanced breast cancer Kazuhiro Araki, Yasuo
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More information(NEO-)ADJUVANT THERAPY FOR HER-2+ EBC
(NEO-)ADJUVANT THERAPY FOR HER-2+ EBC Rebecca Dent, MD FRCP (Canada) Senior Consultant, National Cancer Center Singapore Associate Professor, Duke-NUS www.abc-lisbon.org When to question a pathology report?
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationRuth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory University, Chief of
Endocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 9 th 2013 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
More informationUpdate HER2. Rupert Bartsch. Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna
Update HER2 Rupert Bartsch Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna HER2: A Unique Story of Success Analysis of outcome in
More informationPredicting outcome in metastatic breast cancer
Predicting outcome in metastatic breast cancer Aleix Prat, MD, PhD Medical Oncology Department Translational Genomics and Targeted Therapeutics in Solid Tumors Monday, 15 th January, Manchester, UK Disclosures
More informationThe Role of Angiogenesis Inhibition in Breast Cancer Today: Lessons Learned
The Role of Angiogenesis Inhibition in Breast Cancer Today: Lessons Learned Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education UCSF Helen Diller Family Comprehensive
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More information10/15/2012. Overcoming Endocrine Therapy Resistance. The Problem in ER+ Tumors is Endocrine Therapy Resistance
Overcoming Endocrine Therapy Resistance Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Slide Credits: Hope Rugo, MD The Problem in ER+ Tumors is Endocrine Therapy Resistance
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More informationCustomizing Therapeutic Strategies in the Management of Metastatic Breast Cancer
Customizing Therapeutic Strategies in the Management of Metastatic Breast Cancer Vandana G Abramson, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Breast Cancer
More informationMedia Release. Basel, 3 June 2012
Media Release Basel, 3 June 2012 Roche s targeted investigational breast cancer medicine, trastuzumab emtansine (T-DM1), reduced the risk of cancer worsening or death by 35 percent in pivotal phase III
More informationNadia Harbeck Breast Center University of Cologne, Germany
Evidence in Favor of Taxane Based Combinations and No Anthracycline in Adjuvant and Metastatic Settings Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations
More informationASCO 2017 BREAST CANCER HIGHLIGHTS
Post-ASCO 24 th June 2017, Dolce La Hulpe, Belgium ASCO 2017 BREAST CANCER HIGHLIGHTS Martine J. Piccart-Gebhart, MD, PhD Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast
More informationPRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients
PRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients Amelia B. Zelnak, M.D., M.Sc. Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute
More information